272 related articles for article (PubMed ID: 30616405)
1. Etanercept biosimilar SB-4.
Pelechas E; Drosos AA
Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
[TBL] [Abstract][Full Text] [Related]
2. ABP 501 for the treatment of rheumatoid arthritis.
Pelechas E; Voulgari PV; Drosos AA
Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
[TBL] [Abstract][Full Text] [Related]
3. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
4. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.
Song YW; Park YB; Kim J
Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
6. GP2015 as a promising therapy for rheumatoid arthritis.
Fitton J; Giollo A; Buch MH
Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
[TBL] [Abstract][Full Text] [Related]
9. Etanercept for the treatment of rheumatoid arthritis.
Zhao S; Mysler E; Moots RJ
Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
[TBL] [Abstract][Full Text] [Related]
10. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
[TBL] [Abstract][Full Text] [Related]
11. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
12. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
[TBL] [Abstract][Full Text] [Related]
13. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
[TBL] [Abstract][Full Text] [Related]
14. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
15. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
[TBL] [Abstract][Full Text] [Related]
16. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
Tarallo M; Onishchenko K; Alexopoulos ST
J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
Park SK; Park SH; Lee MY; Park JH; Jeong JH; Lee EK
Clin Ther; 2016 Nov; 38(11):2430-2446.e3. PubMed ID: 27771177
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
20. New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.
Miranda-Hernández MP; López-Morales CA; Perdomo-Abúndez FC; Salazar-Flores RD; Ramírez-Ibanez ND; Pérez NO; Molina-Pérez A; Revilla-Beltri J; Flores-Ortiz LF; Medina-Rivero E
J Immunol Res; 2016; 2016():9697080. PubMed ID: 27382576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]